Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Normosol-R and 5% Dextrose is a sterile, nonpyrogenic solution of balanced electrolytes and dextrose intended for intravenous administration. Manufactured by ICU Medical, it contains a specific blend of sodium chloride, sodium acetate, sodium gluconate, potassium chloride, and magnesium chloride hexahydrate, along with 5% dextrose. The electrolyte profile is designed to approximate the principal ions of normal plasma, providing an isotonic environment with a physiologic sodium-to-chloride ratio. It is primarily indicated for the parenteral replacement of acute extracellular fluid volume losses in clinical settings such as surgery, trauma, burns, or shock. Additionally, it serves as an adjunct for restoring circulatory volume in cases of moderate blood loss and provides a minimal source of carbohydrate calories to help maintain blood glucose levels.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on multiple electrolytes and dextrose injection.